Successful third Eurobond issue for Mölnlycke
Gothenburg, 7 February 2017
Mölnlycke Health Care, a world-leading medical solutions company, successfully launched on 6 February a EUR 500 million bond, maturing in February 2025, with an annual fixed coupon of 1,875%.
Following a well-attended road show in December 2016, there was strong and widespread investor demand for the bond issue, which was more than 5 times oversubscribed.
“This reconfirms market confidence in Mölnlycke and our sound, long-term corporate strategy” , says Stefan Fristedt, CFO.
The bond issue will be used for general corporate purposes and will enable Mölnlycke to extend its debt maturity profile at an attractive cost, increase financial flexibility and support the Group’s continued growth. The company will stay well within its financial leverage policy after the bond issue.
Demand came from leading investors in all regions: Germany/Austria 44%, the Nordics 16%, UK/Ireland 15%, France 13%, Switzerland 5%, BeNeLux 4% and Other 3%. Asset managers were the leading investor type with 74%, followed by insurance/pension funds with 11%, while banks contributed with 10%, official institutions and other with 5%.
For more information, please contact Stefan Fristedt, CFO, +46 31 352 3746.
Mölnlycke Health Care is a world-leading medical products and solutions company that equips healthcare professionals to achieve the best patient, clinical and economic outcomes. We design and supply products and solutions for use in wound treatment, pressure ulcer and infection prevention and surgery. Our products and solutions provide value for money supported by clinical and health economic evidence.
Mölnlycke Health Care employs around 7,500 people and is owned by Investor AB. The company headquarters are in Gothenburg, Sweden and we operate in 100 countries worldwide. Since 2007, the company belongs to Investor AB, the leading owner of Nordic-based international companies, founded by the Wallenberg family a hundred years ago. For more information, please visit www.molnlycke.com.